Abstract | BACKGROUND: OBJECTIVES: We conducted an open study to determine the efficacy and tolerability of calcipotriol cream as monotherapy and in conjunction with psoralen plus ultraviolet A (PUVA) in the treatment of vitiligo. METHODS: Twenty-six patients with vitiligo affecting 5-40% of their skin were recruited. Twenty-two were treated with twice-daily topical calcipotriol monotherapy (50 microg g(-1)) and four were placed on combination treatment with twice-daily topical calcipotriol 50 microg g(-1) in conjunction with topical or oral 8-methoxypsoralen PUVA three times weekly. RESULTS: Treatment was well tolerated at all sites and no adverse effects were reported. After a therapy time of 3-9 months (mean 6 months), 77% (17 of 22) of those treated with monotherapy showed 30-100% improvement, and three of the four patients on combination treatment showed good response. CONCLUSIONS: Topical calcipotriol appears to be an effective and well-tolerated treatment for vitiligo and can be safely used in conjunction with PUVA, but controlled studies are necessary to exclude the possibility of spontaneous repigmentation.
|
Authors | M Ameen, V Exarchou, A C Chu |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 145
Issue 3
Pg. 476-9
(Sep 2001)
ISSN: 0007-0963 [Print] England |
PMID | 11531840
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Dermatologic Agents
- calcipotriene
- Calcitriol
|
Topics |
- Adolescent
- Adult
- Calcitriol
(analogs & derivatives, therapeutic use)
- Child
- Child, Preschool
- Dermatologic Agents
(therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- PUVA Therapy
- Treatment Outcome
- Vitiligo
(drug therapy, pathology)
|